The Potential Impact of Magnesium Supplementation on Cisplatin-Induced Nephrotoxicity in Adult Male Albino Rats

Wafaa Ibrahim Soliman and Nashwa Mohamad Mohamad Shalaby

1 Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Zagazig University, Al sharqia, Egypt.

Abstract

Background: Cisplatin has been considered one of the most effective chemotherapeutic agents. It is associated with numerous toxicities at therapeutic doses like ototoxicity, gastrotoxicity, myelosuppression, allergic reactions and nephrotoxicity. The synergistic effects of Cisplatin and magnesium deficiency are believed to contribute to renal dysfunction. Aim: The aim of this study was to study the nephrotoxicity of cisplatin and evaluate potential impact of magnesium supplementation on such toxicity. Materials and Methods: Thirty-two adult male albino rats were divided into four equal groups. Group I served as (Control group). Group II (magnesium treated group) received single injection of magnesium sulphate (90mg/kg). Groups III (Cisplatin treated group) received single injection of 5 mg/kg body weight of cisplatin and Group IV (Cisplatin and magnesium treated group) received single injection of 90mg/kg magnesium sulphate and 5mg of cisplatin. After 14 days, biochemical parameters in serum were studied: creatinine, BUN, magnesium and inflammatory marker (IL-6) levels. Kidneys were examined by light microscope as well. Results: results indicated that: serum levels of the creatinine, IL-6 and BUN of treated rats showed a highly significant increased compared to control animals, whereas serum magnesium showed highly significant decreased. Magnesium supplementation reverse these changes. In conclusion: Our study demonstrated that cisplatin induced randomized in the kidney function and Mg supplementation ameliorates it. It is recommended to do further investigations to determine the role of magnesium in cisplatin induced nephrotoxicity.

Keywords: Cisplatin, Magnesium, Nephrotoxicity, Chemotherapy.

Introduction

Cisplatin (cis-diammine-dichloroplatinum II) (CP) has been considered one of the most effective chemotherapeutic agents, used for treatment of a variety of human solid tumors. Activity has been proved against a variety of tumors, particularly of head and neck, esophageal, ovarian, testicular, bladder and lung cancers (Baek et al., 2003).

Such effective anticancer activity is associated with numerous toxicities at therapeutic doses as ototoxicity, gastrotoxicity, myelosuppression and allergic reactions, but the main dose-limiting toxicity is nephrotoxicity (Hartmann and Lipp, 2003; Milleret et al., 2010). About 25% to 35% of patients develop evidence of nephrotoxicity following a single dose of cisplatin (Lee et al., 2009).

The exact mechanism of nephrotoxicity induced by cisplatin remains incompletely understood (Pabla and Dong, 2008). The pathophysiology of cisplatin-induced renal toxicity includes four major mechanisms: (1) proximal tubular injury, (2) oxidative stress, (3) inflammation, (4) vascular injury. Proximal tubular injury involves several different mechanisms like mitochondrial dysfunction (Sugiyama et al., 1989), DNA damage (Leibbrandt et al., 1995), dysregulation of cell-cycle proteins (Megyesi et al., 2004), activation of the mitogen-activated protein kinase (MAPK) signaling pathways (Jo et al., 2005), direct toxicity to renal tubular epithelial cells (Ciarimboli et al., 2005), and apoptosis (Wei et al., 2007 and Yang et al., 2008).
Unbound cisplatin in the plasma is freely filtered by the glomerulude to low molecular weight and uncharged character. Most of the cisplatin is trapped within the renal cortex (Safirstein et al., 1984; Launay-Vacher et al., 2008). Kidney contributes to its nephrotoxicity (Kuhlmann et al., 1997; Kodama et al., 2014).

Role in supporting health and life. Also it is involved in over 600 enzymatic reactions including energy metabolism and protein synthesis (de Baaij et al., 2015).

Additionally, magnesium acts as a cofactor for more than 30 enzymes in the body, including binding to ATP for kinase reactions, and affects permeability of excitable membranes and neuromuscular transmission (Benson, 2003) as well as nervous tissue electrical potential (Long and Romani, 2014).

Furthermore, magnesium is considered crucial for controlling extra cellular fluid volume, Na+/K+-ATPase, cellular uptake of solutes, driving force for secondary active transport, and neuromuscular transmission (Benson, 2003).

Magnesium deficiency, characterized by increased inflammation and oxidative stress (Malpuech-Brugere et al., 2000) which results from an imbalance between Mg intake, absorption, and renal losses as well as increased metabolic demands (Mazur et al., 2007; Nielsen, 2010).

The synergetic effects of CP and Mg deficiency are believed to contribute to renal dysfunction (Landon et al., 2013).

Precisely how Mg deficiency promotes CP-induced kidney injury is not known, and little has been done to prevent it.

The aim of this study was to evaluate the potential impact of magnesium supplementation on nephrotoxicity induced by cisplatin treatment in adult male albino rats.

**Materials and Methods**

**Ethical Consideration of Study**

The experimental procedures and the use of laboratory animal were approved by the Animal Research Committee in Zagazig University. Painless procedures were conducted. Animal housing and handling were ethically considered.

**Animals**

In this study 32 male Sprague-Dawley albino mature rats, weighing 200-220 g, were used. Animals were fed ad libitum and housed in pairs in steel cages, having a temperature-controlled environment (22 ± 2°C) with 12 h light/dark cycles.

To abolish gender difference in this study, male rats were used as estrogen itself promotes nephrotoxicity induced by CP (Nematbakhsh et al., 2012; Pezeshki et al., 2012).

The concentration of cisplatin in the proximal tubular cells is 5 times higher than the serum concentration and thus such an accumulation in

Magnesium is an essential ion to the human body, plays an important

**Experimental Protocol**

The experimental animals were randomly divided into four equal groups. Group I served as (Control group). Group II (magnesium treated group) received single (i.p.) injection of magnesium sulphate (90 mg/kg). Groups III (Cisplatin treated group) received single (i.p.) injection of 5 mg/kg body weight of cisplatin and magnesium treated group) received single (i.p.) injection of 90 mg/kg magnesium sulphate and 5 mg of

The dosage of cisplatin was decided according to the previous work of Ikeguchiet al. (2000). They evaluated the toxicity of cisplatin in chemotherapy in rats. The toxicity of cisplatin was analyzed in tumor-free Dongyu rats. Seven rats per group were given an i.p. injection of various doses of cisplatin (7, 8, 9, 10 or 11 mg/kg) with laparotomy under chloroform anesthesia. The volume of cisplatin solution administered was adjusted with physiological saline to 100 ml/kg body weight. The rats were observed for 14 days after administration of cisplatin, and the day of death was recorded. The 50% lethal dose (LD50) of cisplatin was calculated by the graphic approximation method (Finney, 1952). The calculated LD50 was 10 mg/kg of cisplatin. They used half of the LD50 concentration of cisplatin (5 mg/kg) in their experiments, and the volume of solution administered was adjusted to 100 ml/kg body weight (cisplatin, 50 mg/ml).

Other studies of Parlakpinaret al. (2002); Do Amaral et al. (2008); Lee et al. (2009); Choi et al. (2009) support the single dosage of cisplatin (5 mg/kg) proven to causenephrotoxicity.

Also duration of drug-treatment was decided according to the previous study of Han et al., (2008), who revealed that in the rat model, Mg depletion as a side effect of CP may occur 2 weeks after CP administration. And that, alteration in serum creatinine may lag several days behind actual renal injury.

The dosage of magnesium was decided according to the previous work of Mochizuki et al. (1998). They evaluated the toxicity of a single dose of magnesium sulfate in rats. They administered Magnesium sulfate once at dose levels of 90, 130, 200, 300 and 450 mg/kg to rats of both sexes. Deaths occurred in the 200 mg/kg and above groups in both sexes. The LD50 values were 206 mg/kg for males and 174 mg/kg for females. In the surviving animals, in the 130 mg/kg and above groups, tonic convulsions, abnormal gait and tachypnea were seen.
Rats’ body weight were recorded daily. At the end of experiment (14 days), blood samples were obtained from each rat then all animals were scarificated under light ether anathesia, serum was collected and stored at -20 °C until measurement. The kidneys were removed and weighed then stained for histopathological studies.

**Biochemical parameters**

**Blood urea nitrogen, Serum creatinine and Serum magnesium level**

Blood urea nitrogen was determined using “Urease-GLDH”: enzymatic UV test according to Thomas method (Thomas, 1998) using DiaSys reagent kits.

Serum creatinine was determined by using kinetic test without deproteinization according to Newman and Price method (Newman and Price , 1999) using DiaSys reagent kits.

Serum magnesium (Mg) level was determined using quantitative kits according to (Simonsen et al., 1947)

**Measurement of serum IL-6**

Serum IL-6 estimated by ELISA technique using kits supplied by Cytimmune sciences INC,8075 Green mead Drive.College park Mary Land 20740.

**Tissue parameters**

Kidneys were immediately dissected out and grossly inspected to assess any gross abnormalities them washed with cold normal saline and used for histopathological study.

**Light microscope examination**

The kidneys were fixed in 10% formalin solution. After fixation, tissues were embedded in paraffin blocks and processed for 5 μ thickness sections. These sections were stained by Hematoxylin and Eosin stains (Horobin and Bancroft, 1998) and then examined by light microscope.

**Statistical analysis**

Data were analyzed by Statistical Package of Social Science (SPSS), software version 22.0 (SPSS Inc., 2013).

**Results**

No rats died during or after the injections.

---

**As regard body weight and kidney weight** At the beginning of the experiment, the initial animals’ weight was recorded with non-significant differences between the different groups (Table 1).

After the experiment, there was significant decrease in body weight and increase in kidney weight in CP treated group when compared with control group. Magnesium significantly prevented, but did not normalize, cisplatin-induced weight loss in magnesium and CP treated group. While Mg alone had no significant effect (Table 1).

**As regard blood urea nitrogen and serum creatinine:**

A highly significant increase in BUN and serum Creatinine levels were observed in cisplatin treated group when compared with that in control group. Mg supplementation at the dosages of 90 mg/kg could significantly reduce the increase in BUN and serum Creatinine levels compared with that in CP treated group. While Mg at the dose of 90 mg/kg alone had no observable effect on levels of both (Table 2).

**As regard serum magnesium level**

There was significant decrease in serum Mg level in cisplatin treated rats when compared with control group (Table 2).

**As regard inflammatory marker (IL6)**

A high significant increase in IL-6 was observed in cisplatin treated group when compared with control group. Mg administration modify the inflammatory markers, as there was decrease in IL-6 in cisplatin and Mg treated group when compared with cisplatin treated group (Table 2).

**As regard histopathological changes**

Stained kidney section for the control rats and Mg alone groups were normal when were examined under light microscope (Figs. 1, 2).

Histological abnormalities in kidney tissue were observed in CP treated group as atrophied glomeruli, necrosis in renal tubule, dilated proximal convoluted tubule with slogged epithelium and hemorrhage. (Figs. 3,4,5).

While in Mg and CP treated group markedly attenuation in the histopathological changes were seen (Fig.6).
Table (1): ANOVA one was statistical analysis, comparisons between different rats groups regarding initial, final body weight (gm) and kidney weight (gm). Each group of 8 rats.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control group Mean±SD</th>
<th>Mg group Mean±SD</th>
<th>CP group Mean±SD</th>
<th>Mg+CP group Mean±SD</th>
<th>F</th>
<th>LSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Body weight (gm)</td>
<td>210±5</td>
<td>211±6</td>
<td>210±3</td>
<td>211±2</td>
<td>0.144</td>
<td>&lt;0.0001**a</td>
</tr>
<tr>
<td>Final Body weight (gm)</td>
<td>222±6</td>
<td>220±3</td>
<td>198±5</td>
<td>218±3</td>
<td>50.093</td>
<td>0.99 N.S</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.77 N.S a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001**b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.77 N.S b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>kidney weight (gm)</td>
<td>0.54±0.05</td>
<td>0.54±0.03</td>
<td>0.59±0.02</td>
<td>0.56±0.05</td>
<td>2.836</td>
<td>0.34 N.S c</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SD: Standard Deviation, *: significant (p<0.05), **: highly significant (p<0.01), a=versus control, b=versus Mg, c=versus CS.
Table (2): ANOVA one was statistical analysis, comparisons between different rats groups regarding serum level of BUN (mg/dl), creatinine (mg/dl), Mg 1 (mg/dl ) and IL-6 (pg/Ml).Each group of 8 rats.

<table>
<thead>
<tr>
<th>Groups Parameter</th>
<th>Control Mean±SD</th>
<th>Mg Mean±SD</th>
<th>CS Mean±SD</th>
<th>Mg+CS Mean±SD</th>
<th>F</th>
<th>LSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUN (mg/dl)</td>
<td>50.7±9.14</td>
<td>45.2±4.14</td>
<td>98.1±19.11</td>
<td>53.4±8.95</td>
<td>26.942</td>
<td>0.72 N.S a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001** b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001** c</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>0.33±0.04</td>
<td>0.27±0.04</td>
<td>0.50±0.07</td>
<td>0.44±0.04</td>
<td>35.739</td>
<td>0.17 N.S a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001** b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.17 N.S c</td>
</tr>
<tr>
<td>Mg (mg/dl)</td>
<td>4.53±0.1</td>
<td>4.54±0.1</td>
<td>3.33±0.1</td>
<td>4.5±0.2</td>
<td>162.880</td>
<td>0.99 N.S a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.00022** a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.0029** b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001** c</td>
</tr>
<tr>
<td>IL-6 (pg/Ml)</td>
<td>1.87±0.89</td>
<td>1.88±0.80</td>
<td>2.55±0.1</td>
<td>1.9±0.33</td>
<td>2.296</td>
<td>0.99 N.S a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.08 N.S a</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.09 N.S b</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.11 N.S c</td>
</tr>
</tbody>
</table>

SD: Standard Deviation, *: significant (p<0.05), **: highly significant (p<0.01), a=versus control, b=versus Mg, c=versus CS
Fig. (1): A photomicrograph of kidney section of a control rat group showing normal glomeruli (G) and normal renal tubule (arrow). (H & E X 40)

Fig. (2): A photomicrograph of kidney section of Magnesium treated group showing normal glomeruli (G) and normal renal tubule (arrow). (H & E X 40)
Fig.(3): A photomicrograph of kidney section of a cisplatintreated group showing atrophied glomerulus (G) and acute necrosis in renal tubule (arrow). (H & E X 40)

Fig.(4): A photomicrograph of kidney section of a cisplatintreated group showing the dilated Proximal Convoluted Tubule with slogged of epithelium (arrow). Note the tubular lumen (L) filled with cellular debris and elevated tissue in interstitium (I) indicative of necrotic cell. (H & E X 40)
Fig. (5): A photomicrograph of kidney section of a cisplatin treated group showing area of hemorrhage. (H & E X 40)

Fig. (6): A photomicrograph of kidney section of a cisplatin and Magnesium treated group showing normal glomeruli (G) and normal renal tubule (arrow). (H & E X 40)

**Discussion**

Cisplatin is one of the most achieved successes in the war on cancer. Since the accidental discovery over four decades ago, it has been widely used as chemotherapeutic (Wang and Lippard, 2005).

The side effects of cisplatin is considered as major limiting factor in its use, which include neurotoxicity, ototoxicity, nausea, vomiting, and nephrotoxicity (Pasetto et al., 2006).

Renal toxicity is a well-known adverse effect of cisplatin treatment. Despite intensive prophylactic measures, renal toxicity still affects a large number of patients treated with it (Daugaard et al., 1988).

Few days after initiating treatment, about one-third of cisplatin-treated patients exhibited reduced glomerular filtration rates (Pabla and Dong, 2008).

After a single dose of cisplatin (50–100 mg/m²), approximately one-third of the patients develop nephrotoxicity (Lebwohl and Canetta, 1998; Shiraishi et al., 2000).

Increased oxidative stress, inflammation, and apoptosis are considered mechanisms of Cisplatin-induced nephrotoxicity (Pabla and Dong, 2008; Miller et al., 2010; Sanchez-Gonzalez et al., 2011).

Nephrotoxicity is manifested by increased blood urea nitrogen (BUN) and creatinine (Cr), as well
many histological aspects of renal tissue. CP-induced nephrotoxicity disturbs tubular reabsorption of Mg, leading to Mg depletion which enhances nephrotoxicity (Lajer et al., 2005a; Lajer et al., 2005b). The prevention of CP-induced nephrotoxicity in patients remains a great challenge, because there are no specific nephron protective therapies.

The synergistic effects of CP and Mg deficiency are believed to contribute to renal dysfunction (Lajer et al., 2005a). Precisely how Mg deficiency promotes CP-induced kidney injury is not known, and little has been done to prevent it (Miller et al., 2010), for that the main objective of this study was to determine the role of Mg supplementation in CP-induced nephrotoxicity.

In the present study, Cisplatin administration in rats produced a significant decrease in body weight and increase in kidney weight, this is in line with (Rana et al., 2016), who found similar results. They explained that the decreased body weight observed may result from the increased catabolism and decreased food intake. The increase in kidney weight resulted from the edema due to drug induced tubular necrosis.

Also, another study of Ahangarpour et al. (2014), attributed that to the injured renal tubules, with the subsequent loss of the tubular cells to reabsorb water leading to dehydration and loss of body weight.

In contrast of a single dose of cisplatin administration to rat did not induce any significant changes in both body and kidney weights (Habib et al., 2015). This was probably due to short time of study (3 days).

According to De Francisco and Rodríguez (2013) there is a strong relationship between renal function and magnesium level. As study of 550 type 2DM patients with no known kidney disease indicated that lower magnesium levels correlated with progressive deterioration of renal function.

In the present study, There was significant decrease in Mg level in cisplatin treated group, this is in agreement with Lajer and Daugaard (1999) who reported that, Cisplatin treatment causes magnesium deficiency in about 90% of patients who did not receive prophylactic magnesium supplementation due to renal tubular magnesium wasting.

The results of a study made by Bodnar et al. (2008) indicated that prophylactic magnesium supplementation, in addition to the prevention side effects that result from magnesium deficiency, can decrease the severity of cisplatin-induced renal damage without interfering with the its anticancer effect. In fact, among cisplatin-treated cancer patients, those given magnesium had nonsignificantly slower disease progression and longer survival times, when compared with patients given a placebo.

Human organic cation transporter 2 (OCT2) is responsible for the uptake of organic cations across the basolateral membrane in kidneys (Fujita et al., 2006).

Moreover, OCT2 is Mg-dependent and hypomagnesemia causes upregulation of OCT2, which increases the accumulation of CP in the kidney (Filipskiet al., 2009; Yokoo et al., 2009).

Cisplatin induces hypomagnesemia through its renal toxicity by a direct injury to mechanisms of magnesium reabsorption in the ascending limb of the loop of Henle as well as the distal tubule (Lajer and Daugaard, 1999).

Possible symptoms of hypomagnesemia can be impossible to distinguish from symptoms related to the underlying disease or the treatment with chemotherapy. Existing studies on how to supplement magnesium during treatment with cisplatin have focused mainly on the effect on serum magnesium levels and erythrocyte magnesium concentrations but both parameters are poor indicators of body magnesium stores (Lajer and Daugaard, 1999; Lajer et al., 2005b).

As long as the relationship between hypomagnesemia and possible complications thereof remains poorly elucidated, it seems reasonable to try to avoid hypomagnesemia. The best results seem to be provided by adding magnesium to the pre- and post-hydration fluids (Lajer and Daugaard, 1999; Lajer et al., 2005b).

In our study, biochemical markers of serum confirmed that, cisplatin in a single dose of 5 mg/kg produced significant nephrotoxicity as indicated by a significant increase in BUN and serum creatinine levels. This is in agreement with Bokemeyer et al. (1996) who reported that cisplatin (5 mg/kg) can cause an elevation in BUN levels at least 3 days after cisplatin has been administered. Magnesium supplementation of cisplatin treated rats attenuated the cisplatin-induced nephrotoxicity as shown in decrease in the serum levels of BUN and serum creatinine.

Our results are in parallel with the outcomes of the study of Willox et al. (1986) who, revealed that supplementation with 16 mEq Mg was beneficial in reducing renal tubular damage in patients with testicular cancer receiving cisplatin, while Bodnar et al. (2008) demonstrated that 40 mEq Mg supplementation had nephron protective effects during chemotherapy with cisplatin in patients with epithelial ovarian cancer.

Muraki et al. (2012) showed that hydration with 8 mEq Mg and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin.

Muraki et al. (2013) also showed that 20 mEq Mg supplementation may be beneficial in preventing cisplatin-induced nephrotoxicity in patients with esophageal or hypopharyngeal cancer.

Yoshida et al. (2014) reported that 8 mEq Mg preloading before cisplatin administration significantly reduced cisplatin-induced nephrotoxicity in 496 patients with thoracic malignancies.

Mg supplementation is being considered an option for cisplatin-based chemotherapy. Prospective studies since 2007 have examined the use of low-volume hydration in combination with Mg supplementation. Studies showed that low-volume hydration with 16 mEq Mg supplementation in cisplatin-based chemotherapy led to no increase in creatinine in only 35.3% of patients (Yoshida et al., 2007).
According to Hotta et al. (2013) low-volume hydration (2.500 ml) with 4 mEq Mg supplementation before and after cisplatin administration was associated with slightly worse renal toxicity during all cycles of chemotherapy, without significance. Horinouchi et al. (2013) examined the safety of low-volume hydration (1,550 – 2,050 ml) with 8 mEq Mg supplementation; however, renal function during all courses of cisplatin administration was slightly worse.

There was strong evidence that Cisplatin-induced renal injury was caused by the accumulated exposure of the drug in the tubules (Kannan and Jain, 2000) in which the glomerular filtration rate was reduced and followed by an increase of BUN and serum creatinine levels (Edelstein, 2008). Other laboratories had established well proven rat models, in which Cisplatin was administrated with a single intraperitoneally (i.p) injection at 5–10 mg/kg (Ravi et al., 1995).

In the current study, such animals were given one dosage of Cisplatin (5 mg/kg) and renal function parameters, such as BUN and serum creatinine levels, as well as morphology characteristics, were observed. There were obvious pathological changes 5 days after injection, which were all attenuated by Mg co-treatment. Thus, magnesium might have potential protective effect against the renal damage induced by Cisplatin. The rational of obtaining biochemical parameters is due to the fact that, alterations in serum creatinine may lag several days behind actual changes in GFR (Mazur et al., 2014).

Regarding inflammatory markers, numerous studies have connected Mg deficiency with enhanced inflammation in the intestines, heart (Chmielniska et al., 2005; Scanlan et al., 2007), and lungs (Nasulewicz et al., 2004).

Adequate Mg balance has been reported to reduce the risk of inflammation (Dibaba and Xun, 2014).

Magnesium deficiency induced inflammation, can lead to increased TNF-α, IL-6, and IL-1 production in rats (Weglicki et al., 1992; Malpuech-Brugère et al., 1999; Shogi et al., 2002), supporting a link between magnesium and, inflammation, which were consistent with our results.

In contrast, previous studies in humans have not found a correlation between magnesium levels and secreted cytokines (Mezad et al., 2002; Nowacki W et al., 2009). These studies were limited by small samples sizes, measured serum cytokine levels in non-randomized patients, or exposed diluted blood to a high LPS concentration.

Also, Habib et al. (2015) found that CP (12 mg/kg) did not increase renal cytokines at 48 h. However, when CIS was combined with Mg deficiency, renal IL-6 and IL-1β protein levels were significantly elevated.

Experimental Mg deficiency in rats induces a clinical inflammatory syndrome characterized by leukocyte and macrophage activation, synthesis of inflammatory cytokines and acute phase proteins, extensive production of free radicals. An increase in extracellular Mg concentration decreases inflammatory effects (Rayssiguier and Mazur, 2005).

In humans, an inverse association between markers of chronic inflammation and Mg intake has been reported on serum levels (Rodriguez-Moran and Guerrero-Romero, 2004; Song et al., 2005; Bo et al., 2006; Song Y et al., 2007).

The inverse association between Mg and C-reactive protein suggested that Mg deficiency might be involved in the development of low chronic inflammatory syndrome, which can modulate metabolic disorders; Mg supplementation has been shown to reduce CRP blood levels in patients with heart failure. Even if, in epidemiological studies, the association between Mg and inflammatory markers is not always evidenced (Bo and Psu, 2008).

Several studies have been performed to assess the activation of pro-inflammatory cells in Mg deficiency. Mg-deficient rats are more sensitive to immune stress, as measured by TNF α response, following an endotoxin challenge. Increasing extracellular Mg concentration in vivo or in vitro decreased the inflammatory response as shown by chemiluminescence studies or cytokine production (Rayssiguier et al., 2006; Mazur et al., 2007).

Long-term Mg deficiency also results in inflammation and oxidative stress (Blache et al., 2006).

Many studies have suggested that magnesium sulfate (MgSO4) solution has anti-inflammatory properties in many conditions (Dabbagh et al., 2009; Mirkheshti et al., 2012; James, 2009; Singh et al., 2008).

Also, Sugimoto et al. (2012) stated that MgSO4 is safe and well tolerated, and their findings suggest that magnesium could be used therapeutically as a broad-spectrum anti-inflammatory agent. In addition, it has also been demonstrated in a number of studies that magnesium can modulate cellular events involved in inflammation while activation of leukocyte and macrophage and the release of inflammatory cytokines are the characteristic features of this inflammatory syndrome (Mazur, et al., 2007; Rayssiguier et al., 2010). Among the main proposed mechanisms for the anti-inflammatory effects of MgSO4, the 'phosphoinositide 3-kinase/Akt pathway' is one of the most important ones. Meanwhile, another main mechanism seems to be the suppressing role of magnesium throughout the inflammatory process by the 'activation of N-methyl-d-aspartate (NMDA) receptors. Since, magnesium is a natural antagonist of calcium ion and MgSO4, which acts through inhibition of 'N-methyl-D-aspartate dependent cellular pathways' (James, 2009; Rayssiguier et al., 2010).

On the other hand, it has been demonstrated that decreased plasma levels of magnesium can activate inflammatory neuromediators via the activation of 'neuroendocrinological pathways' (Iezhitsa et al., 2011).

The histopathological evidences further confirmed our biochemical findings. Besides significantly decreasing the levels of creatinine and BUN, Mg supplementation with cisplatin ameliorated its certain nephrotoxic effects in the histopathological
examination, such as tubular degeneration, nuclear condensation, apoptosis and inflammation. Cisplatin-induced extensive tubular degeneration and the other histological alterations were also revealed in the previous studies (Davis et al., 2001; Sahu et al., 2011; Ozkol et al., 2012; Al-Kharusi et al., 2013).

Magnesium supplementation greatly attenuate histopathological damage present in cisplatin treated rats. Similar results were found in a study off(Malvika et al., 2015).

In contrast to that, a study of Soltani et al.(2013), they found no protective effect of magnesium supplementation on cisplatin induced histopathological damage of nephrotoxicity. Notably, they used oral preparation of magnesium in diabetic rats.

However, Ashrafi et al. (2012) concluded that Mg supplementation is not nephroprotective against CP-induced nephrotoxicity. Added to that, under some conditions, supplementation may promote kidney toxicity. This controversy of the effect of Mg supplementation on cisplatin induced nephrotoxicity might be due to different reasons; the use of different doses and routes of administration of Mg supplementation.

Also, the fact that >90% of total body magnesium is intracellular, compartmentalized within organelles, bound to protein, or complexed to ATP (Romani,2007).

Extracellular ionized magnesium is readily measurable, but intracellular magnesium, which is not measured clinically and does not correlate with extracellular magnesium levels, is the biologically relevant form(Franz, 2004).

This limitation in our ability to accurately evaluate magnesium status has been a critical barrier to progress in understanding the prevalence and impact of magnesium deficiency (Shils,1999) therefore further studies are required to determine the exact role of magnesium in cisplatin induced nephrotoxicity.

References


Malpuech-Brugere C, Nowacki W, Gueux E et al. (1999): Accelerated thymus involution in magnesium-deficient rats is related to enhanced


SPSS Inc (2013): SPSS for windows, version 22.0. Chicago, SPSS Inc. 

http://www.unimunester.de/imperia/md/content/ziv/service/softwre/pspss/handbuecher/englisch/spss_brief_guide_22.0.pdf

الملخص العربي
التأثير المحتمل لمكملات الماغنسيوم على السمية الكلوية التي يسببها السيسبلاتين في ذكور الجرذان البيضاء البالغة

وفاء إبراهيم سليمان ونشوى محمد شلبي

المقدمة: يعتبر سيسبلاتين واحد من ادوية العلاج الكيميائي الأكثر فعالية. ويرتبط استخدامه بالعديد من الآثار السمية في الجرعات العلاجية مثل تسمم أذني, تسمم الجهاز الهضمي, وأمراض الحساسية وسمية كلية. ويعد أن الآثار المستمرة للسيسبلاتين ونقص الماغنسيوم من أسباب الفشل الكلوي.

هدف البحث: تم أجراء هذا البحث لدراسة الآثار السامة لسيسبلاتين على الكلية وتقييم الآثار المحتملة للمكملات الماغنسيوم عليها في ذكور الجرذان البيضاء.


وتم تجميع النتائج وتحليلها بطرق إحصائية مناسبة ووضعها في جداول وصور وتم مناقشتها. النتائج: من هذه الدراسة تم استنتاج ما يلي: المجموعة المعالجة بالسيسبلاتين ارتفعت بها نسبة الكراتنين، البروبيوميدين، درجات الالتهابات بالمقارنة بالمجموعة الضابطة السالبة مع انخفاض نسبة الماغنبيوم. في حين أن المجموعة المعالجة بالماغنبيوم والسيسبلاتين قل هذا التأثير. الخلاصة: عقار السيسبلاتين يؤدي التسمم الكلوي وأعطى الماغنبيوم وقليل من هذا الآثر.

الوصيات: إجراء مزيد من الدراسات لمعرفة دور الماغنبيوم في تقليل التسمم الكلوي الناجم عن استخدام عقار السيسبلاتين.

1 قسم الطب الشرعي والسموم - كلية الطب البشري - جامعة الزقازيق